ChipAgents Raises $74M to Scale an Agentic AI Platform to Accelerate Chip Design
17.2.2026 16:00:00 CET | Business Wire | Press Release
ChipAgents, the category leader for Agentic AI platforms in the semiconductor design industry, announced it has closed an oversubscribed $50 million Series A1 funding round, bringing total capital raised to $74 million. The round was led by Matter Venture Partners, a TSMC-backed HardTech VC firm, with participation from existing investors Bessemer Venture Partners, Micron, MediaTek, and Ericsson.
As part of the investment, Wen Hsieh, Founding Managing Partner of Matter VP, will join ChipAgents' Board of Directors, bringing over two decades of expertise and relationships in semiconductor design and manufacturing.
Building the AI Workforce for Chip Design Companies
This new capital will enable ChipAgents to aggressively scale its Agentic AI platform, expand its engineering and research organization, and accelerate global deployment of multi-agent chip teams. ChipAgents is building the foundational AI infrastructure for chip design, with coordinated AI Agents that can plan, reason, execute, and continuously improve across complex silicon programs. By transforming chip development into an AI-native, outcome-driven system, ChipAgents is redefining semiconductor innovations.
“We’re building an Agentic AI workforce for the semiconductor industry,” said William Wang, CEO and Founder of ChipAgents. “Our multi-agent AI teams are not just copilots or AI assistants; they actually take ownership. They read specifications, break down objectives, discuss and implement solutions, validate results, and iterate relentlessly. This is not incremental productivity software. It’s a revolutionary AI execution platform for silicon design.”
“As chip complexity explodes and experienced chip design talent becomes the limiting factor, the future will belong to hybrid human-AI teams with the best AI Agent infrastructure,” Wang added. “ChipAgents enables small IC design teams to operate like much larger organizations that can move at startup speed. This funding accelerates our mission to make AI-driven chip innovations the default model for how all silicon will be designed, built, and shipped.”
Strategic Partnership with Industry Leaders
The investment by Matter Venture Partners, a VC firm with deep roots across the global semiconductor ecosystem, reinforces confidence in ChipAgents’ vision to build the Agentic AI platform powering the next generation of silicon innovation. With leading foundries fabricating the vast majority of the world’s most advanced chips, alignment with investors embedded in this ecosystem positions ChipAgents at the center of a structural shift toward AI-native chip development.
"The semiconductor industry is entering a phase where the limits to chip design productivity are no longer the tools themselves," said Wen Hsieh, Founding Managing Partner of Matter Venture Partners. "The limits are now talent availability, human bandwidth and design iteration speed. ChipAgents addresses this constraint directly with an Agentic AI platform capable of significantly scaling engineering and design capacity alongside advanced manufacturing progress. As the AI ecosystem demands increasingly complex, higher-performing silicon, we believe ChipAgents will be essential for any chip company that wants to shape the future of AI and compute.”
Market Momentum and Customer Traction
Building on the momentum of its Series A that was completed a few months ago, ChipAgents has achieved 140x year-over-year ARR growth and has expanded deployments to 80 leading semiconductor companies, securing several multi-year, multi-million-dollar licensing agreements. The team has scaled from 10 to 46 employees and relocated its headquarters from Santa Barbara to a new state-of-the-art facility in Santa Clara, placing the company at the center of the global semiconductor ecosystem. Across Tier-1 semiconductor programs in live production environments, ChipAgents is delivering step-function performance gains:
- 15x faster specification reading and comprehension
- 240x reduction in formal assertion generation time
- 100% code and functional coverage through formal verification
- 400x faster UVM environment generation
These results translate into significantly compressed verification cycles, full design visibility, and a new level of execution velocity across complex digital IC design programs, enabling teams to ship more silicon with greater speed, confidence and control.
World-Class Advisory Board Expands
Sandeep Bharathi, President of Marvell’s Data Center Group, joined ChipAgents’ Advisory Board, bringing over two decades of experience leading chip development for hyperscale cloud and enterprise infrastructure. His expertise in scaling complex SoC programs from design through high-volume production will help guide ChipAgents through its rapid growth.
“Semiconductor development continues to grow in complexity as systems scale across cloud and enterprise infrastructure. The industry must rethink how engineering teams are supported. ChipAgents is exploring how AI can create design and verification workflows, and I look forward to advising the company as it advances this mission,” said Sandeep Bharathi.
Bharathi joins an advisory board that already includes Wally Rhines, former CEO of Mentor Graphics (now Siemens EDA); Raúl Camposano, former CTO of Synopsys; Jack Harding, former CEO of Cadence; John Bowers, Electrical Engineering pioneer, and Erez Tsur, former CEO of Cadence Israel.
About ChipAgents
ChipAgents is an Agentic AI platform that transforms specifications and code into production-ready RTL, verification assets, and automated root-cause analysis, dramatically shortening design and verification cycles. Founded in 2024, the company brings autonomous AI Agents into production semiconductor workflows, serving both design and verification engineers and embedded systems teams at leading semiconductor companies worldwide. The company is headquartered in Santa Clara, California. For more information, visit chipagents.ai
About Matter Venture Partners
Matter Venture Partners is a Silicon Valley-based venture capital firm backing exceptional founders building the most advanced semiconductor, electronics, and Physical AI innovations. With decades of operational expertise and deep strategic relationships, Matter Venture Partners pairs technical insight with long-term conviction to help scale category-defining HardTech startups.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260217568914/en/
Contacts
Media Contact:
press@alphadesign.ai
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom